EI
ACET icon

EAM Investors’s Adicet Bio ACET Stock Holding History

EAM Investors’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-8,236
Closed -$2.63M – 246
2022
Q1 		$2.63M Buy
+8,236
New +$1.89M 0.49% 64

Other funds holding ACET

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

EAM Investors's ACET Position: Q2 2022 in Review

EAM Investors sold out of Adicet Bio (ACET) in Q2 2022, closing a stake of 8,236 shares — an estimated $2.63M sold.

EAM Investors first reported a position in ACET in Q1 2022 and held it in 1 quarter. The position peaked at $2.63M in Q1 2022. 101 funds tracked by Wall St. Rank hold ACET as of Q2 2022.

  • EAM Investors reported no remaining Adicet Bio position as of Q2 2022 after selling out during the quarter.
  • EAM Investors sold 8,236 Adicet Bio shares in Q2 2022, an estimated $2.63M.
  • EAM Investors first reported a position in Adicet Bio in Q1 2022 and held it in 1 quarter.
  • EAM Investors's Adicet Bio position peaked at $2.63M in Q1 2022.
  • 101 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2022.

Based on EAM Investors's 13F filing for Q2 2022, filed 12 Aug 2022.